$VBIO 8-K SEC Filings

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Unsolicited Interest Reinforces Velocity's Strategic Value as Valion Bio Evaluates Opportunities to Advance Entolimod

Interim CEO Dean Zikria’s initial review prioritizes Entolimod and pipeline advancement, commercialization of Velocity Bioworks, and strategic opportunities to maximize the value of the Company’s integrated capabilities

Velocity Bioworks successfully completes initial evaluation of LarmorBio’s BioScan-NMR™ platform, generating data supporting the continued development of continuous, real-time, non-invasive bioprocess monitoring of cell size, density, vi...

With Section 232 Tariffs Reshaping Biotech, Valion Bio’s Velocity Bioworks Capitalizes on Domestic CDMO Surge

Third Side Letter — Closing under Series B Preferred Purchase Agreement

Jensen, who as CEO led Nasdaq-listed biotech Allarity Therapeutics' refocusing around a single lead asset, cites Valion's rare combination of government funding, FDA designations, human safety data and wholly owned U.S. manufacturing

Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity

This CONSULTING AGREEMENT (this “Agreement”) with an effective date of September 22, 2026 (“Effective Date”) is made by and between Valion Bio, Inc. (the “Company” or “Valion”), and Dean Zikria (“Consultant”).